Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
RVMD - Revolution Medicines, Inc.
Market Cap 3.48B P/E - EPS this Y 12.70% Ern Qtrly Grth -
Income -519.21M Forward P/E -10.18 EPS next Y -13.10% 50D Avg Chg 25.00%
Sales 742k PEG - EPS past 5Y - 200D Avg Chg 36.00%
Dividend N/A Price/Book 3.66 EPS next 5Y - 52W High Chg -
Recommedations 1.50 Quick Ratio 15.10 Shares Outstanding 167.04M 52W Low Chg 92.00%
Insider Own 2.14% ROA -24.95% Shares Float 153.31M Beta 1.43
Inst Own 104.25% ROE -40.73% Shares Shorted/Prior 17.17M/16.84M Price 32.78
Gross Margin - Profit Margin - Avg. Volume 1,021,824 Target Price 60.08
Oper. Margin -77,524.66% Earnings Date Nov 4 Volume 3,063,320 Change 4.06%
Healthcare | Biotechnology | United States
About Revolution Medicines, Inc.

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

Revolution Medicines, Inc. News
12/12/24 One Revolution Medicines Insider Raised Their Stake In The Previous Year
12/05/24 Revolution Medicines Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters' Option to Purchase Additional Shares
12/04/24 Revolution Medicines price target raised to $87 from $82 at Guggenheim
12/03/24 Revolution Medicines Announces Pricing of Upsized $750.0 Million Public Offering of Common Stock and Pre-Funded Warrants
12/02/24 Revolution Medicines Announces Commencement of Public Offering of Common Stock
12/02/24 Revolution Medicines Reports Early Data Supporting Ongoing Study of Cancer Therapies
12/02/24 Revolution Medicines Provides Clinical Updates from its RAS(ON) Inhibitor Portfolio
11/27/24 Revolution Medicines to Host RAS(ON) Inhibitor Clinical Update Webcast on December 2, 2024
11/09/24 Decoding Revolution Medicines Inc (RVMD): A Strategic SWOT Insight
11/07/24 Revolution Medicines Inc (RVMD) Q3 2024 Earnings Call Highlights: Strategic Advances Amid ...
11/06/24 Revolution Medicines Reports Third Quarter 2024 Financial Results and Update on Corporate Progress
11/05/24 Revolution Medicines to Participate in Upcoming Investor Conferences
10/30/24 Revolution Medicines to Report Financial Results for Third Quarter 2024 After Market Close on November 6, 2024
10/25/24 Revolution Medicines Presents Initial Data from RMC-9805 Monotherapy Study in Patients with Advanced Pancreatic Ductal Adenocarcinoma
10/23/24 Revolution Medicines Presents Updated Data from RMC-6236 Monotherapy Study in Patients with Advanced Pancreatic Ductal Adenocarcinoma
10/21/24 Revolution Medicines Announces First Patient Dosed in Phase 3 Study Evaluating RMC-6236 in Previously Treated Patients with Metastatic Pancreatic Ductal Adenocarcinoma
10/07/24 Revolution Medicines to Deliver Multiple Presentations at the 2024 AACR-NCI-EORTC Symposium and Host Investor Webcast
09/14/24 Revolution Medicines, Inc. (RVMD): Among Hedge Funds’ Top Biotech Stock Picks
08/09/24 Revolution Medicines First Half 2024 Earnings: US$1.51 loss per share (vs US$1.64 loss in 1H 2023)
08/08/24 Q2 2024 Revolution Medicines Inc Earnings Call
RVMD Chatroom

User Image TearStonkUp Posted - 3 days ago

$RVMD have been patiently waiting and finally got an entry in $42.80’s… Now to cook until January 😌

User Image JuggernautRaider Posted - 3 days ago

$PPBT your PPS expectations are reasonable @iambaron . @PPBT4LYFE knows: @PurpleBiotech is a WINNER! They need to start hiring North American employees with pancreatic cancer experience from $BMY or $RVMD or even $NVCR to show they are preparing for launch. They may need a phase 3 but a 2 month OS in 2L pancreatic cancer is significant.

User Image Capitulation_0 Posted - 3 days ago

$RVMD data readout mid Jan. Let's move!

User Image Capitulation_0 Posted - 3 days ago

$MRK is saving their cash to buy $RVMD. You heard it here first or second...

User Image Capitulation_0 Posted - 4 days ago

$RVMD RVMD will have early clinical data from RMC-9805 G12D KRAS(ON) PDAC next month The ASCO GI 25, or the 2025 ASCO Gastrointestinal Cancers Symposium, will be held on January 23-25, 2025.

User Image Capitulation_0 Posted - 4 days ago

$RVMD SCHROEDER THILO 12/05/2024 1,304,347 $46.00 This is one of the biggest insider buys for sub 10B company I've seen in some time...

User Image Capitulation_0 Posted - 4 days ago

$RVMD Looking more like MRK needs RVMD. Someone start a rumor already!

User Image Capitulation_0 Posted - 4 days ago

$RVMD MRK just blew up Tigit & Lag3. They need to go shopping!

User Image Capitulation_0 Posted - 5 days ago

$RVMD Stupid action. Sell all your shares fools.

User Image Capitulation_0 Posted - 5 days ago

$RVMD $APLS same action. Initial morning pop then sell off. Getting tired of the same action. At least $TGTX is acting nicely.

User Image Capitulation_0 Posted - 5 days ago

$RVMD Insider buying big last week. Stock has come down from $60. I seen peak sale as high as 11B by analyst. IF a BP wanted signal to everyone that M&A is back, this one makes sense around 10B

User Image StockAutoPro Posted - 1 week ago

$RVMD: At $35.23. Equity buy with a target of $42. Oncology-focused biotech with multiple late-stage assets in the pipeline.

User Image angelinvesting369 Posted - 1 week ago

$NVDA $TSLA $RVMD Revolution Medicines director just bought $60,000,000 worth of stock as the co enters ph 3 for their revolutionary pancreatic cancer drug 👀

User Image angelinvesting369 Posted - 1 week ago

$TSLA $NVDA $RVMD insiders sell for many reasons but buy for only one reason 🚀https://www.investing.com/news/insider-trading-news/revolution-medicines-director-schroeder-acquires-599m-in-stock-93CH-3762307

User Image Capitulation_0 Posted - 1 week ago

$RVMD MRK needs RVMD. It's come down from mid 60's where you could've argued that it was too expensive for a takeout of 80-100% premium. At mid 40's, BO premium of 80-100% should be more tolerable.

User Image Capitulation_0 Posted - 1 week ago

$RVMD Hard to justify BP's that are saying de-risked assets are too expensive to buy when they're trading at 1-2x peak sales.

User Image Capitulation_0 Posted - 1 week ago

$RVMD Every bio is selling off.. $60 Jan calls seeing some action.

User Image EmSol Posted - 1 week ago

$CADL sorry I’m bull but that’s not true.. the problem with $CADL is also the science completion. My favorite for lung and pancreatic cancer is far $RVMD. I’m in since $15 and triple my investment. $RVMD has wonderful result, check out I keep $CADL like I believe we need 2 treatment and both are good for patient, the only other reason I keep its a low market cap versus $RVMD

User Image Capitulation_0 Posted - 1 week ago

$RVMD 2 year to approval. 5-10B peak sales. What the hell are BPs waiting for? Right, for LLY, you'd rather do a 15B buyback instead of buying a 15B asset that will pay you 5-10B for the next 15+ years. BP CEOs are so risk adverse.

User Image Capitulation_0 Posted - 1 week ago

$RVMD LLY and other BPs complaining that de-risked asset valuation are too high to do deals. This trading at 2x peak revenue, perhaps, 1x revenue if you account everything in the pipeline.

User Image Capitulation_0 Posted - 1 week ago

$RVMD If BPs were to change their tune from small to big.. This one is one of the most promising.

User Image Capitulation_0 Posted - 1 week ago

$RVMD should reclaim $60 soonish..

User Image padd1 Posted - 1 week ago

$RVMD 60 Million Insider buy at Revolution Medicines Inc!! Market is sleeping?! Insider trade alert 🚨: Thilo Schroeder Title(s): Dir $RVMD - Revolution Medicines, Inc. Trade date: 12-5-2024 P - PURCHASE: 1,304,347 shares @ $46.00 Position change: +21% Total value: +$59,999,962 $CDIO $ACXP $PPBT $SNTI

User Image dButterz Posted - 1 week ago

$RVMD 🤑https://gribio.com/gri-bio-to-participate-in-the-virtual-investor-closing-bell-series/

User Image padd1 Posted - 1 week ago

$RVMD BREAKING: Massive New Insider Purchase at Revolution Medicines Inc. A director at $RVMD has just reported buying $60M of the company's stock. This purchase was made through a venture fund where he is the managing partner. This is the first insider purchase he has made in over a year. $CDIO $ACXP $PPBT $SNTI

User Image RonIsWrong Posted - 1 week ago

$RVMD

User Image Rubiks_KubeMD Posted - 1 week ago

$RVMD it sucks Steve Jobs missed out on this treatment

User Image Rubiks_KubeMD Posted - 1 week ago

$RVMD super bullish. I'm in early and long. My wife plays tennis with a lady who HAD recurrent pancreatic cancer. She was enrolled in the attached trial and she is playing tennis tournaments with no symptoms. Could be a game changer imo

User Image erevnon Posted - 2 weeks ago

Needham maintains Revolution Medicines $RVMD at Buy and lowers the price target from $68 to https://marketsblock.com/stock-upgrades-and-downgrades/

User Image Quantumup Posted - 2 weeks ago

Needham trims the PT on $RVMD to $62 was $68/Buy, after updating its model to account for the closing of $RVMD's upsized public offering. Needham said it looks forward to $RVMD's update during JP Morgan for future timelines of the data and other clinical development updates and reiterated its Buy rating as they continue to see meaningful potential for the RAS-ON platform, either by combining two RAS-ON drugs or by combining with other treatments.

Analyst Ratings
Barclays Overweight Sep 27, 24
HC Wainwright & Co. Buy Aug 12, 24
JP Morgan Overweight Aug 8, 24
Wedbush Outperform Aug 8, 24
Needham Buy Aug 8, 24
Barclays Overweight Jul 18, 24
Oppenheimer Outperform Jul 16, 24
B of A Securities Buy Jul 16, 24
HC Wainwright & Co. Buy Jul 16, 24
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Anders Jack Chief Financial Offi.. Chief Financial Officer Dec 18 Sell 25.9018 1,775 45,976 76,416 12/20/23
GOLDSMITH MARK A See Remarks See Remarks Dec 18 Sell 25.9018 8,165 211,488 376,167 12/20/23
Cislini Jeff General Counsel General Counsel Dec 18 Sell 25.9017 1,229 31,833 37,284 12/20/23
Kelsey Stephen Michael See Remarks See Remarks Dec 18 Sell 25.9016 2,088 54,083 271,633 12/20/23
Horn Margaret A Chief Operating Offi.. Chief Operating Officer Dec 15 Sell 26.27 7,993 209,976 101,467 12/19/23
Horn Margaret A Chief Operating Offi.. Chief Operating Officer Dec 15 Option 4.09 5,000 20,450 109,460 12/19/23
Cislini Jeff General Counsel General Counsel Nov 20 Sell 21.6966 1,500 32,545 38,513 11/20/23
Horn Margaret A Chief Operating Offi.. Chief Operating Officer Oct 25 Option 0.54 7,500 4,050 104,460 10/25/23
GOLDSMITH MARK A See Remarks See Remarks Oct 24 Option 0.49 35,000 17,150 384,332 10/24/23
Anders Jack Chief Financial Offi.. Chief Financial Officer Oct 23 Option 3.39 24,524 83,136 78,191 10/23/23
Cislini Jeff General Counsel General Counsel Sep 28 Sell 28.58 2,000 57,160 40,013 10/02/23
GOLDSMITH MARK A See Remarks See Remarks Sep 01 Option 0.83 30,000 24,900 387,386 09/06/23
GOLDSMITH MARK A See Remarks See Remarks Sep 01 Sell 35.04 40,000 1,401,600 35,424 09/06/23
Weber Barbara Director Director Sep 01 Sell 35.07 15,000 526,050 15,825 09/06/23
Weber Barbara Director Director Sep 01 Option 2.93 15,000 43,950 30,825 09/06/23
Anders Jack Chief Financial Offi.. Chief Financial Officer Sep 01 Sell 35.05 20,000 701,000 55,094 09/06/23
Anders Jack Chief Financial Offi.. Chief Financial Officer Sep 01 Option 2.68 20,000 53,600 75,094 09/06/23
Cislini Jeff General Counsel General Counsel Jul 31 Sell 26.02 1,500 39,030 43,227 08/01/23
Horn Margaret A See Remarks See Remarks Mar 17 Sell 21.78 1,230 26,789 100,062 03/21/23
Anders Jack Chief Financial Offi.. Chief Financial Officer Mar 17 Sell 21.78 665 14,484 55,233 03/21/23
Kelsey Stephen Michael See Remarks See Remarks Mar 17 Sell 21.78 1,230 26,789 326,369 03/21/23
Wang Xiaolin See Remarks See Remarks Mar 17 Sell 21.78 714 15,551 58,813 03/21/23
Schroeder Thilo Director Director Mar 07 Buy 21.32 650,000 13,858,000 1,553,134 03/10/23
GOLDSMITH MARK A See Remarks See Remarks Feb 22 Option 0.49 45,000 22,050 251,872 02/23/23
Horn Margaret A Chief Operating Offi.. Chief Operating Officer Oct 31 Sell 20.4053 17,767 362,541 17,767 11/02/22
Wang Xiaolin See Remarks See Remarks Sep 19 Sell 19.0426 735 13,996 31,235 09/21/22
Kelsey Stephen Michael See Remarks See Remarks Sep 19 Sell 19.0426 1,267 24,127 288,819 09/21/22
Horn Margaret A See Remarks See Remarks Sep 19 Sell 19.0426 1,267 24,127 62,512 09/21/22
Anders Jack Chief Financial Offi.. Chief Financial Officer Sep 19 Sell 19.0426 449 8,550 29,956 09/21/22
GOLDSMITH MARK A See Remarks See Remarks Aug 11 Option 0.49 10,000 4,900 206,872 08/15/22
GOLDSMITH MARK A See Remarks See Remarks Aug 09 Option 0.49 10,336 5,065 196,872 08/10/22
Schroeder Thilo Director Director Jul 22 Buy 20.00 250,000 5,000,000 1,221,315 07/26/22
Kim Lorence H. Director Director Jul 22 Buy 20.00 50,000 1,000,000 60,500 07/25/22
Wang Xiaolin See Remarks See Remarks Jun 17 Sell 17.7495 665 11,803 31,970 06/22/22
Kelsey Stephen Michael See Remarks See Remarks Jun 17 Sell 17.7495 1,145 20,323 290,086 06/22/22
Horn Margaret A See Remarks See Remarks Jun 17 Sell 17.7495 1,145 20,323 63,779 06/22/22
Anders Jack See Remarks See Remarks Jun 17 Sell 17.7495 406 7,206 20,405 06/22/22
Third Rock Ventures III, L.P. 10% Owner 10% Owner Jun 08 Sell 20.25 419,901 8,502,995 5,104,130 06/10/22
Exter Neil Director Director Jun 08 Sell 0.00 06/10/22
Schroeder Thilo Director Director Mar 25 Buy 24.85 42,725 1,061,716 971,315 03/29/22
Schroeder Thilo Director Director Mar 22 Buy 23.48 232,364 5,455,907 928,590 03/24/22
Schroeder Thilo Director Director Mar 17 Buy 20.08 168,051 3,374,464 696,226 03/21/22
Horn Margaret A See Remarks See Remarks Mar 17 Sell 18.6145 321 5,975 63,987 03/21/22
Kelsey Stephen Michael See Remarks See Remarks Mar 17 Sell 18.6162 321 5,976 290,294 03/21/22
Wang Xiaolin See Remarks See Remarks Mar 17 Sell 18.6142 240 4,467 31,698 03/21/22
GOLDSMITH MARK A See Remarks See Remarks Mar 17 Sell 18.6141 1,023 19,042 185,599 03/21/22
Anders Jack See Remarks See Remarks Mar 17 Sell 18.6162 159 2,960 19,875 03/21/22
Schroeder Thilo Director Director Mar 10 Buy 20.91 43,510 909,794 528,175 03/14/22
Schroeder Thilo Director Director Mar 07 Buy 19.14 246,438 4,716,823 484,665 03/09/22
Schroeder Thilo Director Director Feb 18 Buy 23.17 1,088,227 25,214,220 238,227 03/04/22